Vivek Bhaskaran

Vivek Bhaskaran

Auto-generated profile, based on publicly available information

Vivek Bhaskaran

Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 02115, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CPCarmela Passaro
Carmela Passaro
QAQuazim Alayo
Quazim Alayo
IDIsabel DeLaura
Isabel DeLaura
JMJohn McNulty
John McNulty
KGKorneel Grauwet
Korneel Grauwet
HNHiroshi Nakashima
Hiroshi Nakashima
Purpose: Glioblastoma (GBM) is resistant to standard of care. Immune checkpoints inhibitors (such as anti-PD-1 mAbs) efficiently restore antitumor T-cell activity. We engineered a new oncolytic herpes simplex virus (oHSV) expressing a single-chain antibody against PD-1 (scFvPD-1) to evaluate its efficacy in mouse models of GBM. Experimental Design: NG34scFvPD-1 expresses the human GADD34 gene transcriptionally controlled by the Nestin promoter to allow replication in GBM cells and a scFvPD-1 cDNA transcriptionally controlled by the CMV promoter. ELISA assays were performed to detect binding of scFvPD-1 to mouse and human PD-1. In vitro cytotoxicity and replication assays were performed to measure NG34scFvPD-1 oncolysis, and scFvPD-1 expression and secretion were determined. In vivo survival studies using orthotopic mouse GBM models were performed to evaluate the therapeutic potency of NG34scFvPD-1. Results: NG34scFvPD-1–infected GBM cells express and secrete scFvPD-1 that binds mouse PD-1. The introduction of the scFvPD-1 sequence in the viral backbone does not alter the oncolytic properties of NG34scFvPD-1. In situ NG34scFvPD-1 treatment improved the survival with a tail of durable survivorship in 2 syngeneic immunocompetent mouse models of GBM. Mice that survived the first GBM challenge rejected the second challenge of GBM when implanted in the contralateral hemisphere. However, this was not true when athymic mice were employed as the recipients of the second challenge, consistent with the need for an intact immune system to obtain a memory response. Conclusions: NG34scFvPD-1 treatment induces a durable antitumor response in 2 preclinical mouse models of GBM with evidence for antitumor memory.

25 January 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
VBVivek Bhaskaran
Vivek Bhaskaran
MNMichal Nowicki
Michal Nowicki
MIMahmoud Idriss
Mahmoud Idriss
MJMiguel A. Jimenez
Miguel A. Jimenez
GLGianmarco Lugli
Gianmarco Lugli
PPPierpaolo Peruzzi
Pierpaolo Peruzzi
MicroRNA deregulation is a consistent feature of glioblastoma, yet the biological effect of each single gene is generally modest, and therapeutically negligible. Here we describe a module of microRNAs, constituted by miR-124, miR-128 and miR-137, which are co-expressed during neuronal differentiation and simultaneously lost in gliomagenesis. Each one of these miRs targets several transcriptional regulators, including the oncogenic chromatin repressors EZH2, BMI1 and LSD1, which are functionally interdependent and involved in glioblastoma recurrence after therapeutic chemoradiation. Synchronizing the expression of these three microRNAs in a gene therapy approach displays significant anticancer synergism, abrogates this epigenetic-mediated, multi-protein tumor survival mechanism and results in a 5-fold increase in survival when combined with chemotherapy in murine glioblastoma models. These transgenic microRNA clusters display intercellular propagation in vivo, via extracellular vesicles, extending their biological effect throughout the whole tumor. Our results support the rationale and feasibility of combinatorial microRNA strategies for anticancer therapies.

17 April 2017 in Oncogene
Verified
Journal Article
Open access
PDF file
MNM S Nandhu
M S Nandhu
AKA Kwiatkowska
A Kwiatkowska
VBV Bhaskaran
V Bhaskaran
JHJ Hayes
J Hayes
BHB Hu
B Hu
MVMariano S Viapiano
Mariano S Viapiano
Molecular profiling of glioblastomas has revealed the presence of key signaling hubs that contribute to tumor progression and acquisition of resistance. One of these main signaling mechanisms is the nuclear factor-kappa B (NF-κB) pathway, which integrates multiple extracellular signals into transcriptional programs for tumor growth, invasion and maintenance of the tumor-initiating population. We show here that an extracellular protein released by glioblastoma cells, fibulin-3, drives oncogenic NF-κB in the tumor and increases NF-κB activation in peritumoral astrocytes. Fibulin-3 expression correlates with a NF-κB-regulated ‘invasive signature’ linked to poorer survival, being a possible tissue marker for regions of active tumor progression. Accordingly, fibulin-3 promotes glioblastoma invasion in a manner that requires NF-κB activation both in the tumor cells and their microenvironment. Mechanistically, we found that fibulin-3 activates the metalloprotease ADAM17 by competing with its endogenous inhibitor, TIMP3. This results in sustained release of soluble tumor necrosis factor alpha (TNFα) by ADAM17, which in turn activates TNF receptors and canonical NF-κB signaling. Taken together, our results underscore fibulin-3 as a novel extracellular signal with strong activating effect on NF-κB in malignant gliomas. Because fibulin-3 is produced de novo in these tumors and is absent from the normal brain, we propose that targeting the fibulin-3/NF-κB axis may provide a novel avenue to disrupt oncogenic NF-κB signaling in combination therapies for malignant brain tumors.

14 February 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MNMohan S. Nandhu
Mohan S. Nandhu
PBPrajna Behera
Prajna Behera
VBVivek Bhaskaran
Vivek Bhaskaran
SLSharon L. Longo
Sharon L. Longo
LBLina M. Barrera-Arenas
Lina M. Barrera-Arenas
MVMariano S Viapiano
Mariano S Viapiano
Purpose: We sought a novel approach against glioblastomas (GBM) focused on targeting signaling molecules localized in the tumor extracellular matrix (ECM). We investigated fibulin-3, a glycoprotein that forms the ECM scaffold of GBMs and promotes tumor progression by driving Notch and NFκB signaling. Experimental Design: We used deletion constructs to identify a key signaling motif of fibulin-3. An mAb (mAb428.2) was generated against this epitope and extensively validated for specific detection of human fibulin-3. mAb428.2 was tested in cultures to measure its inhibitory effect on fibulin-3 signaling. Nude mice carrying subcutaneous and intracranial GBM xenografts were treated with the maximum achievable dose of mAb428.2 to measure target engagement and antitumor efficacy. Results: We identified a critical 23-amino acid sequence of fibulin-3 that activates its signaling mechanisms. mAb428.2 binds to that epitope with nanomolar affinity and blocks the ability of fibulin-3 to activate ADAM17, Notch, and NFκB signaling in GBM cells. mAb428.2 treatment of subcutaneous GBM xenografts inhibited fibulin-3, increased tumor cell apoptosis, and enhanced the infiltration of inflammatory macrophages. The antibody reduced tumor growth and extended survival of mice carrying GBMs as well as other fibulin-3–expressing tumors. Locally infused mAb428.2 showed efficacy against intracranial GBMs, increasing tumor apoptosis and reducing tumor invasion and vascularization, which are enhanced by fibulin-3. Conclusions: To our knowledge, this is the first rationally developed, function-blocking antibody against an ECM target in GBM. Our results offer a proof of principle for using “anti-ECM” strategies toward more efficient targeted therapies for malignant glioma. Clin Cancer Res; 24(4); 821–33. ©2017 AACR.

30 January 2013 in Acta Crystallographica Section F Structural Biology and Crystallization Communications
Verified
Journal Article
Closed access
PDF file
TGTavarekere S. Girish
Tavarekere S. Girish
BVB. Vivek
B. Vivek
MCMelwin Colaço
Melwin Colaço
SMSandra Misquith
Sandra Misquith
BGB. Gopal
B. Gopal

1 January 2019 in Journal of Experimental Neuroscience
Verified
Journal Article
Open access
PDF file
PPPierpaolo Peruzzi
Pierpaolo Peruzzi
VBVivek Bhaskaran
Vivek Bhaskaran
Much is known about microRNA biology and their involvement in essentially any biological processes in eukaryotic cells, including cancer. Now, to take advantage of them in clinics, a change in perspective is needed and a reappraisal of their features is warranted to re-ignite interest and translational hype. As we recently reported, their strength is in numbers, size and simplicity.